Summary
Nuria Oliva-Jorge graduated from Institut Quimic de Sarria, Universitat Ramon Llull (Barcelona, Spain) with a Bachelor of Science in Organic Chemistry. She then received her PhD in Medical Engineering and Medical Physics (MEMP) at the Harvard-MIT Division of Health Sciences and Technology (HST); training under the guidance of Prof Elazer Edelman and Prof Natalie Artzi, Nuria focused on the development of a novel adhesive hydrogel and its use as a model platform to understand how disease microenvironment affects material performance and how to leverage those cues to attain tumor cell-selective delivery of chemotherapy in a local and sustained manner. She then spent one year at Brigham and Women's Hospital (Harvard Medical School) as a NIH Ruth L. Kirschstein post-doctoral fellow within the Organ Design and Engineering Training Program (ODET) at Brigham and Women’s Hospital (Harvard Medical School).
Nuria joined the Almquist Lab at Imperial College London in 2017, where she developed a novel DNA nanotechnology for promoting bone regeneration. During this time, she secured funding from a TECNIOspring PLUS posdoctoral fellowship (within the Marie Sklodowska-Curie Action) and the MedTech SuperConnector Programme, and received the 2019 European Tissue Repair Society Young Investigator Award. She is currently an Imperial College Research Fellow in the department of Bioengineering at Imperial College London. Her group works at the intersection of biomaterials, biology and medicine to develop disruptive technologies to tackle disease.
For more information, visit the Oliva Lab's website.